BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30987833)

  • 21. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
    Chai Y; Wu W; Zhou C; Zhou J
    Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
    Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
    Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.
    Williams E; Martin S; Moss R; Durrant L; Deen S
    Virchows Arch; 2012 Jul; 461(1):33-9. PubMed ID: 22699808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
    Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
    Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
    Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
    Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.
    Londero AP; Orsaria M; Tell G; Marzinotto S; Capodicasa V; Poletto M; Vascotto C; Sacco C; Mariuzzi L
    Am J Clin Pathol; 2014 Mar; 141(3):404-14. PubMed ID: 24515769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
    Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
    Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.